Creon, manufactured by AbbVie. The price is prohibitive for a large number of PC Survivors. Currently there is no generic replacement. The few alternatives are not compatible to patients malabsortion. AbbVie does try to make Creon affordable to some. We hope to demonstrate that all of us should be able to afford Creon.
Whipple Warrior Survivors, is a support group for pancreatic cancer and whipple surgery survivors and their caregivers. We now have over 6000 members world wide, with new members joining everyday.
We celebrate hard won medical mile stones. We give hope when the shocking news of a recurrent cancer has taken hope away. We listen to the caregiver who has just gave his Survivor to the ambulance. We are there for the patient who can't eat, can't sleep, can't stop vomiting, can't stop using the toilet, can't stop the infections, or can't stop crying. We greive when our Warrior on purple wings has left their family and friends.
What we are unable to do is make medical costs affordable. Living with a ressected pancreas or total pancreadectomy requires a lifetime of enzyme replacement. With out enzyme replacement we do not metabilise our food and suffer with malabsorbtion and eventually malnutrition.
Creon is manufactored by AbbVie, which was part of Abbot Labs. In 2013 they seperated from Abbot labs to be a seperate company. AbbVie is the one and only producer of Creon. There is no generic duplicate. The alternative medications are incomplete, not compatable with this condition, and unsuitable.
In the United States AbbVie will charge no fee for the uninsured meeting AbbVie's minimum wage condition. The government pays for patients with low income receiving Medicaid. AbbVie is generous to offer a conveniant $5.00 copay card on all refills to some of us with health insurance.
If you have Obama care the $5.00 copay is only for the first pruchase. There after a $75.00 out of pocket discount is offered. Meaning if insurance requires a $500.00 copay, with the discount you pay $425.00, and not the $5.00 copay.
Patients that are outside any subsidised umbrella, are taking smaller doses to stretch their preciuos supply. Some have given up on Creon and are seeking and taking less expensive alternatives that do little or nothing to help with the absorbtion of essential nutrients.
We hope to demonstrate to AbbVie, their generosity should extend to all in need of Creon. - No one should have to find the price so prohibitive and they must chose to go with out.
